...
首页> 外文期刊>Cancer epidemiology, biomarkers and prevention: A publication of the American Association for Cancer Research >Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression.
【24h】

Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression.

机译:乳腺导管癌进展过程中CpG岛启动子甲基化模式的变化。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aberrant promoter methylation of several known or putative tumor suppressor genes occurs frequently during carcinogenesis, and this epigenetic change has been considered as a potential molecular marker for cancer. We examined the methylation status of nine genes (APC, CDH1, CTNNB1, TIMP3, ESR1, GSTP1, MGMT, THBS1, and TMS1), by quantitative methylation specific PCR. Synchronous preinvasive lesions (atypical ductal hyperplasia and/or ductal carcinoma in situ) and invasive ductal breast carcinoma from 52 patients, together with pure lesions from 24 patients and 12 normal tissues paired to tumor and 20 normal breast distant from tumor were analyzed. Aberrant promoter methylation was detected in both preinvasive and invasive lesions for genes APC, CDH1, CTNNB1, TIMP3, ESR1, and GSTP1. However, hierarchical mixed model and Generalized Estimating Equations model analyses showed that only APC, CDH1, and CTNNB1 promoter regions showed a higher frequency and methylation levels in pathologic samples when compared with normal breast. Whereas APC and CTNNB1 did not show differences in methylation levels or frequencies, CDH1 showed higher methylation levels in invasive tumors as compared with preinvasive lesions (P < 0.04, Mann-Whitney test with permutation correction). The analysis of APC, CDH1, and CTNNB1 methylation status was able to distinguish between normal and pathologic samples with a sensitivity of 67% (95% confidence interval, 60-71%) and a specificity of 75% (95% confidence interval, 69-81%). Our data point to the direct involvement of APC, CDH1, and CTNNB1 promoter methylation in the early stages of breast cancer progression and suggest that they may represent a useful tool for the detection of tumor cells in clinical specimens.
机译:几种已知的或推定的肿瘤抑制基因的异常启动子甲基化在致癌过程中经常发生,这种表观遗传变化被认为是潜在的癌症分子标记。通过定量甲基化特异性PCR,我们检查了九种基因(APC,CDH1,CTNNB1,TIMP3,ESR1,GSTP1,MGMT,THBS1和TMS1)的甲基化状态。分析了52例患者的同步浸润前病变(非典型导管增生和/或导管原位癌)和浸润性导管癌,以及24例与肿瘤配对的12例正常组织和20例远离肿瘤的正常乳房的纯病变。在APC,CDH1,CTNNB1,TIMP3,ESR1和GSTP1基因的侵袭前和侵袭性病变中均检测到异常的启动子甲基化。但是,分层混合模型和广义估计方程模型分析显示,与正常乳房相比,病理样本中只有APC,CDH1和CTNNB1启动子区域显示更高的频率和甲基化水平。 APC和CTNNB1在甲基化水平或频率上没有差异,而CDH1在浸润性肿瘤中的甲基化水平高于浸润前病变(P <0.04,Mann-Whitney检验并进行了排列校正)。对APC,CDH1和CTNNB1甲基化状态的分析能够区分正常样品和病理样品,灵敏度为67%(95%置信区间,60-71%),特异性为75%(95%置信区间,69) -81%)。我们的数据表明APC,CDH1和CTNNB1启动子甲基化直接参与乳腺癌进展的早期阶段,并表明它们可能代表了检测临床标本中肿瘤细胞的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号